OPKO Health (NASDAQ:OPK) Downgraded to “Sell” Rating by Wall Street Zen

OPKO Health (NASDAQ:OPK) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday.

OPK has been the subject of several other reports. Barrington Research reduced their price objective on OPKO Health from $2.25 to $1.50 and set an “outperform” rating for the company in a research report on Monday, March 2nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of OPKO Health in a research note on Thursday, January 22nd. Finally, JPMorgan Chase & Co. started coverage on shares of OPKO Health in a report on Thursday, November 20th. They issued a “neutral” rating for the company. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $2.03.

OPKO Health Price Performance

NASDAQ OPK opened at $1.18 on Friday. OPKO Health has a twelve month low of $1.11 and a twelve month high of $1.95. The company has a debt-to-equity ratio of 0.26, a quick ratio of 3.32 and a current ratio of 3.97. The stock has a market capitalization of $895.70 million, a PE ratio of -3.93 and a beta of 1.50. The stock has a 50-day simple moving average of $1.26 and a 200 day simple moving average of $1.35.

OPKO Health (NASDAQ:OPK) last released its earnings results on Thursday, February 26th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.03. The firm had revenue of $148.50 million for the quarter, compared to analyst estimates of $139.76 million. OPKO Health had a negative return on equity of 17.42% and a negative net margin of 37.19%.The company’s revenue was down 19.1% on a year-over-year basis. During the same quarter last year, the firm posted $0.01 EPS. Research analysts anticipate that OPKO Health will post -0.25 EPS for the current year.

Institutional Investors Weigh In On OPKO Health

Large investors have recently modified their holdings of the stock. Caprock Group LLC acquired a new position in shares of OPKO Health in the 3rd quarter worth approximately $26,000. Zacks Investment Management acquired a new stake in OPKO Health in the 4th quarter valued at $27,000. StoneX Group Inc. acquired a new stake in OPKO Health in the 4th quarter valued at $27,000. Swiss Life Asset Management Ltd bought a new stake in OPKO Health in the third quarter valued at $30,000. Finally, Savant Capital LLC acquired a new position in OPKO Health during the third quarter worth $33,000. 64.63% of the stock is currently owned by institutional investors.

OPKO Health Company Profile

OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.